This study evaluates if magnetic resonance imaging (MRI) identified progression can decrease the frequency or need for repeated prostate biopsy in men on active surveillance for prostate cancer. Diagnostic procedures, such as MRI, may be a less invasive way to check for prostate cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02425592.
PRIMARY OBJECTIVES:
I. Establish HISTOLOGIC progression rate after repeat MRI-ultrasound (US) fusion prostate biopsy in men on active surveillance for prostate cancer.
II. Establish RADIOLOGIC progression rate after repeat MRI-US fusion prostate biopsy in men on active surveillance for prostate cancer.
OUTLINE:
Patients undergo multiparametric magnetic resonance imaging (MP-MRI), MRI-US fusion biopsy, and digital rectal exam at baseline, 12 months, and 24 months. Patients also undergo collection of blood samples every 6 months for 24 months.
Trial PhaseNo phase specified
Trial Typehealth services research
Lead OrganizationYale University
Principal InvestigatorPreston C. Sprenkle
